Efeitos do rocurônio, sugamadex e complexo rocurônio‐sugamadex sobre a coagulação em ratos

Cavalcanti, Ismar Lima; Braga, Estêvão Luiz Carvalho; Verçosa, Núbia; Schanaider, Alberto; Barrucand, Louis; Boer, Hans D. de; Vane, Luiz Antonio

doi:10.1016/j.bjan.2020.08.007

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O rocurônio, um BNM de ação intermediária, tem ganhado destaque devido ao Sugamadex, seu agente reversor eficaz desde 2008 (Barbosa et al, 2020;I.-Y. Chen et al, 2023;Lima Cavalcanti et al, 2020). O Sugamadex, uma γ-ciclodextrina modificada, atua como ligante relaxante seletivo, encapsulando o rocurônio e tornando-o inativo (A. T. Chen et al, 2022;Ji et al, 2023;Rubio-Baines et al, 2023).…”

Section: Introductionunclassified

Sugamadex na reversão da anafilaxia por rocurônio em paciente pediátrico: Relato de caso

Fernandes,

Amorim,

Mendes Filho

2023

RSD

View full text Add to dashboard Cite

Bloqueadores neuromusculares, notadamente o rocurônio, são uma causa proeminente de reações anafiláticas no período perioperatório. O rocurônio, conhecido por sua ação rápida e de duração intermediária, tem ganhado destaque devido aos benefícios do Sugamadex, seu agente reversor, que proporciona reversão ágil e previsível de bloqueio neuromuscular. Relatamos o caso de um paciente de 6 anos, 30 kg, submetido a vídeotoracoscopia assistida (VATS), que apresentou uma reação adversa após a administração de rocurônio, manifestando rubor torácico, taquicardia, hipotensão grave e petéquias generalizadas. Apesar das tentativas de tratamento com adrenalina, não houve melhora na hemodinâmica. Após a administração de Sugamadex, observou-se uma resposta positiva, com aumento da frequência cardíaca e pressão arterial, permitindo a transferência do paciente para a Unidade de Terapia Intensiva Pediátrica. Nesse sentido, este relato de caso teve o objetivo de descrever o tratamento de um episódio de anafilaxia induzida por rocurônio e tratada com a administração de sugamadex.

show abstract

Section: Introductionunclassified

Sugamadex na reversão da anafilaxia por rocurônio em paciente pediátrico: Relato de caso

Fernandes,

Amorim,

Mendes Filho

2023

RSD

View full text Add to dashboard Cite

show abstract

"Coagulation Factors, Influenced or Not, in the Repeated Dose Toxicity Test of a Candidate Vaccine Against Sars-Cov-2?"

Ancuta¹,

Preda²,

Muntean³

2022

Roum Arch Microbiol Immunol

View full text Add to dashboard Cite

"SARS-CoV-2 infection increases the risk of multi-organ systemic complications and venous and arterial thromboembolism. The development of vaccines has proven to be an effective method to combat severe forms of infection. Adverse effects reported after COVID-19 vaccination consisted of local injection site reaction, fatigue, myalgia, or fever as well as sporadic cases of vaccine-induced thrombotic immune thrombocytopenia, especially viral vector vaccines. Objectives: The aim of the study was to evaluate the repeated dose toxicity of a candidate vaccine against SARS-CoV-2, a test in which several parameters were analyzed, including coagulation factors. Materials and methods: The test included 120 rats, of both sexes, divided into six groups (main group, recovery group and control group) at which the human dose, 10X human dose and 1 control adjuvant were tested. The vaccine was administered intranasally, 4 times every two weeks. The final day was after the last administration to the main group and another 30 days from the last administration to the recovery group. On day 0 and the final day, blood was collected for hematological, biochemical, immunological examinations and coagulation tests (Fibrinogen, Prothrombin Time-PT, Activated Partial Thromboplastin Time-aPTT and Thrombin Time-TT). Results: Fibrinogen, in the case of all groups, increased on the final day, except for females from the recovery groups where this parameter decreased by 25%. PT, aPTT and TT, regardless of group or sex, had low values compared to the initial time of the study. On day 0, the values of the coagulation factors were homogeneous, the fibrinogen being between 155-347mg / dL, PT 25.5-57.8 sec, aPTT 61.9-120 sec and TT values of 53-60 sec. On the final day, the group analysis also showed unit values. Fibrinogen increased between 90-116%, PT decreased by 48-71%, aPTT decreased by 59-80%, and TT had values lower by 10-14% compared to the initial day. Conclusions: Increased fibrinogen associated with decreased PT and aPTT is common in human clinical pathology. Fibrinogen, PT, aPTT and TT are the standard parameters of blood clotting assessed in toxicity tests. The results obtained in the study represent a preliminary phase which, corroborated with the results of the other tests, supports the conclusion that the candidate vaccine does not have toxicological potential, the coagulation factors not being influenced after its repeated administration. Keywords: SARS-CoV-2, coagulation factors, rat, vaccine"

show abstract

Efeitos do rocurônio, sugamadex e complexo rocurônio‐sugamadex sobre a coagulação em ratos

Cited by 2 publications

References 18 publications

Sugamadex na reversão da anafilaxia por rocurônio em paciente pediátrico: Relato de caso

Sugamadex na reversão da anafilaxia por rocurônio em paciente pediátrico: Relato de caso

"Coagulation Factors, Influenced or Not, in the Repeated Dose Toxicity Test of a Candidate Vaccine Against Sars-Cov-2?"

Contact Info

Product

Resources

About